Common Errors Made in the Diagnosis and Treatment of Epilepsy

ABSTRACT

Learning from one's mistakes is the best learning tool in medicine and this applies as well to epilepsy. This article is a compilation of some of the frequent mistakes that are made in the evaluation and management of patients with epilepsy. It encompasses errors in the clinical diagnosis that result in the choice of the erroneous antiepileptic drug (AED), errors in the way auxiliary tests like the electroencephalogram and magnetic resonance imaging studies are ordered, mistakes in the recognition of subclinical status epilepticus, errors in the selection of AEDs, consequences of the failure to factor in the pharmacokinetic and pharmacodynamic properties of AEDs in the choice and dosification of medication, misconceptions on the expectations of therapeutic effect of AEDs, delay in recognition of refractory epilepsy with consequent delay in a timely identification of patients whose epilepsy can be cured with surgical treatment, and mistakes in the recognition and management of comorbid psychiatric disorders. In addition to a discussion of the reasons for the errors, the article provides practical solutions.

KEYWORDS

Applied pharmacokinetics - antiepileptic drugs - intractable epilepsy - nonepileptic seizures - status epilepticus

REFERENCES

• 1 Kanner A M. Psychogenic pseudoseizures: semiology and pathogenic mechanisms. In: Luders HO, Noachtar S The Epileptic Seizures: Pathophysiology and Clinical Semiology. New York, NY; Churchill Livingstone 2000: 766-773
• 2 Kanner A M. Psychogenic seizures and the supplementary sensory motor area. In: HO Luders The Supplementary Sensory Motor Area. Advances in Neurology. Vol. 70. New York, NY; Raven Press 1996: 461-466
• 3 Kanner A M, Iriarte J. Psychogenic pseudoseizures: differential diagnosis. In: Kotagal P, Luders HO Etiologies of the Epilepsies. San Diego, CA; Academic Press 1999: 509-518
• 4 Jallon P, Latour P. Epidemiology of idiopathic generalized epilepsies.  Epilepsia. 2005;  46(suppl 9) 10-14
• 5 Welty T E. Juvenile myoclonic epilepsy: epidemiology, pathophysiology, and management.  Paediatr Drugs. 2006;  8 303-310
• 6 Kwan P, Brodie M J. Early identification of refractory epilepsy.  N Engl J Med. 2000;  342 314-319
• 7 DeLorenzo R J. Epidemiology and clinical presentation of status epilepticus.  Adv Neurol. 2006;  97 199-215
• 8 Treiman D M, Meyers P D, Walton N Y et al.. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group.  N Engl J Med. 1998;  339 792-798
• 9 DeLorenzo R J, Waterhouse E J, Towne A R et al.. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus.  Epilepsia. 1998;  39 833-840
• 10 Brodie M J, Chadwick D W, Anhut H et al.. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.  Epilepsia. 2002;  43 993-1000
• 11 Brodie M J, Perucca E, Ryvlin P, Ben-Menachem E, Meencke H J. Levetiracetam Monotherapy Study Group . Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.  Neurology. 2007;  68 402-408
• 12 Mohanraj R, Brodie M J. Pharmacological outcomes in newly diagnosed epilepsy.  Epilepsy Behav. 2005;  6 382-387
• 13 Privitera M D, Brodie M J, Mattson R H et al.. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy.  Acta Neurol Scand. 2003;  107 165-175
• 14 Arroyo S, Dodson W E, Privitera M D et al.. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy.  Acta Neurol Scand. 2005;  112 214-222
• 15 Trimble M R, Mula M. Antiepileptic drug interactions in patients requiring psychiatric drug treatment. In: Majkowski J, Bourgeois B, Patsalos P, Mattson R Antiepileptic Drugs: Combination Therapy and Interactions. Cambridge; Cambridge University Press 2005: 350-368
• 16 Patsalos P N, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.  Lancet Neurol. 2003;  2 473-481
• 17 Sitsen J, Maris F, Timmer C. Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects.  Eur J Drug Metab Pharmacokinet. 2001;  26(1–2) 109-121
• 18 Pihlsgard M, Eliasson E. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin.  Eur J Clin Pharmacol. 2002;  57 915-916
• 19 Majkowski J, Patsalos P N. Interaction between epileptic and non-epileptic drugs. In: Majkowski J, Bourgeois B, Patsalos P, Mattson R Antiepileptic Drugs: Combination Therapy and Interactions. Cambridge; Cambridge University Press 2005: 139-177
• 20 Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen P J, Mjorndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid.  Eur J Clin Pharmacol. 2004;  59 879-882
• 21 Relling M V, Pui C H, Sandlund J T et al.. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia.  Lancet. 2000;  356 285-290
• 22 Villikka K, Kivisto K T, Maenpaa H, Joensuu H, Neuvonen P J. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors.  Clin Pharmacol Ther. 1999;  66 589-593
• 23 Rowan A J, Ramsay R E, Collins J F et al.. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.  Neurology. 2005;  64 1868-1873
• 24 Leppik I E. Epilepsy in the elderly.  Epilepsia. 2006;  47(suppl 1) 65-70
• 25 Garrard J, Harms S, Hardie N et al.. Antiepileptic drug use in nursing home admissions.  Ann Neurol. 2003;  54 75-85
• 26 Feldkamp J, Becker A, Witte O W, Scharff D, Scherbaum W A. Long-term anticonvulsant therapy leads to low bone mineral density: evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells.  Exp Clin Endocrinol Diabetes. 2000;  108 37-43
• 27 Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy.  Acta Neurol Scand. 1999;  99 269-275
• 28 Annegers J F, Melton III L J, Sun C A, Hauser W A. Risk of age-related fractures in patients with unprovoked seizures.  Epilepsia. 1989;  30 348-355
• 29 Valmadrid C, Voorhees C, Litt B, Schneyer C R. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy.  Arch Neurol. 2001;  58 1369-1374
• 30 Pack A M, Morrell M J. Treatment of women with epilepsy.  Semin Neurol. 2002;  22 289-298
• 31 Engel Jr J, Wiebe S, French J. Practice parameter: temporal lobe and localized neocortical resections for epilepsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons.  Neurology. 2003;  60 538-547
• 32 Mani J, Gupta A, Mascha E et al.. Postoperative seizures after extratemporal resections and hemispherectomy in pediatric epilepsy.  Neurology. 2006;  66 1038-1043
• 33 Semah F, Picot M C, Adam C et al.. Is the underlying cause of epilepsy a major prognostic factor for recurrence?.  Neurology. 1998;  51 1256-1262
• 34 Spooner C G, Berkovic S F, Mitchell L A, Wrennall J A, Harvey A S. New-onset temporal lobe epilepsy in children: lesion on MRI predicts poor seizure outcome.  Neurology. 2006;  67 2147-2153
• 35 Dlugos D J. The early identification of candidates for epilepsy surgery.  Arch Neurol. 2001;  58 1543-1546
• 36 Gilliam F, Kuzniecky R, Faught E et al.. Patient-validated content of epilepsy-specific quality-of-life measurement.  Epilepsia. 1997;  38 233-236
• 37 Lehrner J, Kalchmayr R, Serles W et al.. Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients.  Seizure. 1999;  8 88-92
• 38 Perrine K, Hermann B P, Meador K J et al.. The relationship of neuropsychological functioning to quality of life in epilepsy [see comments].  Arch Neurol. 1995;  52 997-1003
• 39 Boylan L S, Flint L A, Labovitz D L, Jackson S C, Starner K, Devinsky O. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy.  Neurology. 2004;  62 258-261
• 40 Kanner A M, Wuu J, Barry J, Hermann B, Meador K J, Gilliam F. Atypical depressive episodes in epilepsy: a study of their clinical characteristics and impact on quality of life.  Neurology. 2004;  62(suppl 5) A249
• 41 Harris E C, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis.  Br J Psychiatry. 1997;  170 205-228
• 42 Jones J E, Hermann B P, Barry J J, Gilliam F G, Kanner A M, Meador K J. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy.  Epilepsy Behav. 2003;  4(suppl 3) S31-S38
• 43 Kanner A M. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms and treatment.  Biol Psychiatry. 2003;  54 388-398
• 44 Kanner A M. Current review in clinical science. Depression in epilepsy: a neurobiologic perspective.  Epilepsy Curr. 2005;  5 21-27
• 45 Alper K, Schwartz K A, Kolts R L, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.  Biol Psychiatry. 2007;  62 345-354
• 46 Dunn D W, Austin J K, Harezlak J, Ambrosius W T. ADHD and epilepsy in childhood.  Dev Med Child Neurol. 2003;  45 50-54
• 47 Hesdorffer D C, Ludvigsson P, Olafsson E, Gudmundsson G, Kjartansson O, Hauser W A. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children.  Arch Gen Psychiatry. 2004;  61 731-736
• 48 Feldman H, Crumine P, Handen B L, Alvin R, Teodori J. Methylphenidate in children with seizures and attention-deficit disorder.  Am J Dis Child. 1989;  143 1081-1086
• 49 Gross-Tsur V, Manor O, van der Meere J, Joseph A, Shalev R S. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?.  J Pediatr. 1997;  130 670-674
• 50 Ott D, Caplan R, Guthrie D et al.. Measures of psychopathology in children with complex partial seizures and primary generalized epilepsy with absence.  J Am Acad Child Adolesc Psychiatry. 2001;  40 907-914